SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson WW, Weintraub E, Dhankhar P et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009; 3:3749.
  • 2
    Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:18791885.
  • 3
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767777.
  • 4
    Tauraso NM, O'Brien TC, Seligman EB Jr. Problems of influenza virus vaccine standardization. Bull World Health Organ 1969; 41:497506.
  • 5
    Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237247.
  • 6
    Coenen F, Tolboom JT, Frijlink HW. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter? Vaccine 2006; 24:525531.
  • 7
    Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007; 25:64476457.
  • 8
    Willkommen H, Platen S, Staber H. The influence of pH and ionic strength on the single radial immunodiffusion test in qualitative assay of influenza virus haemagglutinin. Acta Virol 1983; 27:407411.
  • 9
    Doms RW, Helenius A, White J. Membrane fusion activity of the influenza virus hemagglutinin. The low pH-induced conformational change. J Biol Chem 1985; 260:29732981.
  • 10
    Gaspar LP, Silva AC, Gomes AM. Hydrostatic pressure induces the fusion-active state of enveloped viruses. J Biol Chem 2002; 277:84338439.
  • 11
    Ishimaru D, Sa-Carvalho D, Silva JL. Pressure-inactivated FMDV: a potential vaccine. Vaccine 2004; 22:23342339.
  • 12
    Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938; 27:493497.
  • 13
    Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993; 37:253262.
  • 14
    Hassantoufighi A, Zhang H, Sandbulte M et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010; 28:790797.
  • 15
    Bucher DJ, Kilbourne ED. A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit. J Virol 1972; 10:6066.
  • 16
    Sultana I, Gao J, Markoff L, Eichelberger MC. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine 2011; 29:26012606.
  • 17
    Air GM, Influenza neuraminidase. Influenza Other Respi Viruses 2012; 6:245256.
  • 18
    Khurana S, Verma S, Verma N et al., Properly folded bacterially expressed H1N1 hemagglutinin globular head ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010; 5:e11548.
  • 19
    Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69:531569.
  • 20
    Silva JL, Foguel D. Hydration, cavities and volume in protein folding, aggregation and amyloid assembly. Phys Biol 2009; 6:015002.
  • 21
    Silva JL, Oliveira AC, Gomes AM et al. Pressure induces folding intermediates that are crucial for protein-DNA recognition and virus assembly. Biochim Biophys Acta 2002; 1595:250265.
  • 22
    Foguel D, Suarez MC, Ferrao-Gonzales AD et al. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci USA 2003; 100:98319836.
  • 23
    Cordeiro Y, Kraineva J, Ravindra R et al. Hydration and packing effects on prion folding and beta-sheet conversion. High pressure spectroscopy and pressure perturbation calorimetry studies. J Biol Chem 2004; 279:3235432359.
  • 24
    Grove SF, Lee A, Lewis T, Stewart CM, Chen H, Hoover DG. Inactivation of foodborne viruses of significance by high pressure and other processes. J Food Prot 2006; 69:957968.
  • 25
    Gogal RM Jr, Kerr R, Kingsley DH et al. High hydrostatic pressure processing of murine norovirus 1-contaminated oysters inhibits oral infection in STAT-1(-/-)-deficient female mice. J Food Prot 2011; 74:209214.
  • 26
    Kingsley DH, Guan D, Hoover DG, Chen H. Inactivation of hepatitis A virus by high-pressure processing: the role of temperature and pressure oscillation. J Food Prot 2006; 69:24542459.
  • 27
    Jurkiewicz E, Villas-Boas M, Silva JL, Weber G, Hunsmann G, Clegg RM. Inactivation of simian immunodeficiency virus by hydrostatic pressure. Proc Natl Acad Sci USA 1995; 92:69356937.
  • 28
    Otake T, Kawahata T, Mori H, Kojima Y, Hayakawa K. Novel method of inactivation of human immunodeficiency virus type 1 by the freeze pressure generation method. Appl Microbiol Biotechnol 2005; 67:746751.
  • 29
    Isbarn S, Buckow R, Himmelreich A, Lehmacher A, Heinz V. Inactivation of avian influenza virus by heat and high hydrostatic pressure. J Food Prot 2007; 70:667673.
  • 30
    Silva JL, Cordeiro Y, Giongo V et al. Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus. J Virol 1992; 66:21112117.
  • 31
    Pontes L, Cordeiro Y, Giongo V et al. Pressure-induced formation of inactive triple-shelled rotavirus particles is associated with changes in the spike protein Vp4. J Mol Biol 2001; 307:11711179.
  • 32
    Tian SM, Ruan KC, Qian JF, Shao GQ, Balny C. Effects of hydrostatic pressure on the structure and biological activity of infectious bursal disease virus. Eur J Biochem 2000; 267:44864494.
  • 33
    Gaspar LP, Mendes YS, Yamamura AM et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008; 150:5762.